Seres Therapeutics, Inc.
MCRB
$17.70
$1.005.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.20M | -19.86M | 32.68M | -15.64M | 88.78M |
| Total Depreciation and Amortization | 1.04M | 1.06M | 1.08M | 10.29M | 1.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | 0.00 | 463.00K |
| Total Other Non-Cash Items | 4.61M | 4.40M | 4.86M | -3.40M | -115.73M |
| Change in Net Operating Assets | -11.65M | 1.10M | -11.71M | -30.13M | -9.59M |
| Cash from Operations | 2.21M | -13.29M | 26.91M | -38.88M | -34.68M |
| Capital Expenditure | -8.00K | -181.00K | -34.00K | -90.00K | -129.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 0.00 | 141.27M |
| Other Investing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Investing | -8.00K | -181.00K | -34.00K | -90.00K | 141.14M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00 | -127.91M |
| Issuance of Common Stock | 61.00K | 0.00 | 1.18M | 1.74M | 17.03M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 61.00K | 0.00 | 1.18M | 1.74M | -110.87M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -1.00K | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.26M | -13.47M | 28.06M | -37.24M | -4.41M |